Market Update: Eli Lilly & Company (NYSE:LLY) – FDA asks panel to weigh benefit, risk of Lilly lung cancer drug

[Reuters] – Eli Lilly & Co.’s experimental lung cancer drug necitumumab improved overall survival by an average of 1.6 months but also increased the risk of sometimes fatal blood clots according to a . . . → Read More: Market Update: Eli Lilly & Company (NYSE:LLY) – FDA asks panel to weigh benefit, risk of Lilly lung cancer drug Similar Articles: Market Update (NYSE:LLY): Eli Lilly wins UK Alimta drug patent case on appeal Company Update (NYSE:LLY): Eli Lilly loses Alimta drug patent case in Germany to Actavis Company Update (NYSE:LLY): Lilly delays submission to market once-daily diabetes drug